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Abstract: Background The heterogeneity and lack of validation of existing severity scores for food allergic
reactions limit standardization of case management and research advances. We aimed to develop and
validate a severity score for food allergic reactions. Methods Following a multidisciplinary experts con-
sensus, it was decided to develop a food allergy severity score (FASS) with ordinal (oFASS) and numerical
(nFASS) formats. oFASS with 3 and 5 grades were generated through expert consensus, and nFASS by
mathematical modeling. Evaluation was performed in the EuroPrevall outpatient clinic cohort (8232
food reactions) by logistic regression with request of emergency care and medications used as outcomes.
Discrimination, classification, and calibration were calculated. Bootstrapping internal validation was fol-
lowed by external validation (logistic regression) in 5 cohorts (3622 food reactions). Correlation of nFASS
with the severity classification done by expert allergy clinicians by Best-Worst Scaling of 32 food reac-
tions was calculated. Results oFASS and nFASS map consistently, with nFASS having greater granularity.
With the outcomes emergency care, adrenaline and critical medical treatment, oFASS and nFASS had
a good discrimination (receiver operating characteristic area under the curve [ROC-AUC]>0.80), clas-
sification (sensitivity 0.87–0.92, specificity 0.73–0.78), and calibration. Bootstrapping over ROC-AUC
showed negligible biases (1.0 × 10−6–1.23 × 10−3). In external validation, nFASS performed best with
higher ROC-AUC. nFASS was strongly correlated (R 0.89) to best-worst scoring of 334 expert clinicians.
Conclusion FASS is a validated and reliable method to measure severity of food allergic reactions. The
ordinal and numerical versions that map onto each other are suitable for use by different stakeholders in
different settings.
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G R A P H I C A L  A B S T R A C T
FASS with ordinal (oFASS- 3, oFASS- 5) and numerical (nFASS) formats that map consistently was developed by multidisciplinary experts' 
consensus and mathematical modeling. Following evaluation, internal and external validation, FASS is a validated and reliable method to 
measure severity of food allergic reactions. oFASS- 3, oFASS- 5, and nFASS are suitable for use by different stakeholders in different settings.
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1  |  INTRODUC TION
Food allergy (FA) has become a significant medical problem in the 
last decades.1,2 Food allergic reactions can affect different organs 
and systems, and present with a wide range of severity from mild 
transient oral symptoms, to severe and even fatal anaphylaxis. In 
fact, FA is one of the main causes of anaphylaxis in the community.3- 7 
The severity of reactions varies between individuals, and within re-
peated reactions in the same individual. Severe reactions are not 
predictable, and allergists have limitations to accurately identify the 
patients at greatest risk of life- threatening reactions.8
The treatment of acute allergic reactions is driven by severity. 
The longer- term management is also guided by the severity of the 
previous reaction(s), and/or by the presumed risk of having a fu-
ture severe reaction.9 With increasing risk (or risk perception) more 
rigorous avoidance of their problem food is needed, and patients 
should carry rescue medication including an adrenaline autoinjector. 
The uncertainty and fear of the severity and outcome of any future 
reaction have a profound negative impact on patients' health- related 
quality of life.10 Current FA risk management strategies are focused 
on clinical, regulatory and industrial collaborations to develop ref-
erence doses that will or not trigger an allergic reaction and to use 
them to guide precautionary allergen labeling, but the severity of 
the reaction is not considered in the process.11,12 Similarly, novel in-
terventions in FA such as allergen immunotherapy or anti- IgE ther-
apy aim to reduce the risk of accidental reactions by increasing the 
amount of allergen tolerated, but the severity of the reactions is not 
included as a primary outcome.13- 16
Severity is therefore a key parameter in FA that needs to be mea-
sured as accurately as possible. Several scoring systems have been 
proposed by different groups to grade severity of anaphylaxis,17- 24 
and of allergic reactions induced by foods,25- 33 drugs,18- 20 insect 
venoms,21- 24 or allergen immunotherapy.34- 37 All the instruments 
are organ based, most of them generated using expert opinion with 
only one using a Delphi methodology.33 The great majority classifies 
severity using ordinal scales (3 to 6 grades) that are not equivalent 
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Abstract
Background: The heterogeneity and lack of validation of existing severity scores for 
food allergic reactions limit standardization of case management and research ad-
vances. We aimed to develop and validate a severity score for food allergic reactions.
Methods: Following a multidisciplinary experts consensus, it was decided to develop a 
food allergy severity score (FASS) with ordinal (oFASS) and numerical (nFASS) formats. 
oFASS with 3 and 5 grades were generated through expert consensus, and nFASS 
by mathematical modeling. Evaluation was performed in the EuroPrevall outpatient 
clinic cohort (8232 food reactions) by logistic regression with request of emergency 
care and medications used as outcomes. Discrimination, classification, and calibration 
were calculated. Bootstrapping internal validation was followed by external validation 
(logistic regression) in 5 cohorts (3622 food reactions). Correlation of nFASS with the 
severity classification done by expert allergy clinicians by Best- Worst Scaling of 32 
food reactions was calculated.
Results: oFASS and nFASS map consistently, with nFASS having greater granularity. 
With the outcomes emergency care, adrenaline and critical medical treatment, oFASS 
and nFASS had a good discrimination (receiver operating characteristic area under the 
curve [ROC- AUC]>0.80), classification (sensitivity 0.87– 0.92, specificity 0.73– 0.78), 
and calibration. Bootstrapping over ROC- AUC showed negligible biases (1.0 × 10−6– 
1.23 × 10−3). In external validation, nFASS performed best with higher ROC- AUC. 
nFASS was strongly correlated (R 0.89) to best- worst scoring of 334 expert clinicians.
Conclusion: FASS is a validated and reliable method to measure severity of food al-
lergic reactions. The ordinal and numerical versions that map onto each other are 
suitable for use by different stakeholders in different settings.
K E Y W O R D S
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making comparisons difficult.38- 40 Furthermore, none of the current 
systems has been validated (ie, the performance has never been 
assessed).
The European Union- funded project Integrated Approaches to 
Food Allergen and Allergy Risk Management (iFAAM) in collabo-
ration with a task force of the European Academy of Allergy and 
Clinical Immunology (EAACI) critically reviewed the available sys-
tems and proposed in an EAACI Position Paper an approach to de-
velop a system to measure severity of allergic reactions.41 Here, we 
report the development and validation of the Food Allergy Severity 
Score (FASS), aligned with the EAACI Position Paper. The report fol-
lows the Transparent Reporting of a multivariable prediction model 
for Individual Prognosis Or Diagnosis (TRIPOD) statement.42
2  |  METHODS
2.1  |  Development of the Food Allergy Severity 
Score (FASS)
2.1.1  |  Premises that FASS must meet
In line with the iFAAM- EAACI expert consensus41 FASS had to meet 
the following premises:
• Have an anatomical basis: as the number of organs/systems in-
volved increase, severity increases.
• Consider laryngeal (Lx), bronchial (BR), cardiovascular (CV), and 
nervous system (NS) involvement as potentially life- threatening, 
even if isolated, and thus more severe than that of other organs/
systems.
• Use variables (symptoms/signs) that are easily/routinely recorded.
• Be applicable to all patient populations (all ages, all foods).
• Be used in different countries.
• Have ordinal (oFASS) and numerical (nFASS) formats that map 
consistently, to facilitate use by different stakeholders in differ-
ent scenarios.
The development of FASS needs to identify the organs/systems 
affected and the specific symptoms and signs associated with their 
involvement in an allergic reaction, since these are the variables 
used to build the score. The identification of organs and systems 
based on anatomy does not pose a problem. However, there are mul-
tiple ways to describe symptoms and signs of allergic reactions and a 
common international terminology is lacking. To overcome this, the 
symptoms as described in the PRACTALL consensus43 have been 
taken as reference.
2.1.2  |  Ordinal Food Allergy Severity Score (oFASS)
The oFASS was built by experts' consensus of different stakehold-
ers (expert allergy clinicians, epidemiologists, basic scientists, repre-
sentatives of food allergic patients) after several rounds of discussion 
at iFAAM project meetings. It has two versions of five (oFASS- 5) and 
three categories (oFASS- 3) (Table 1). We use the term oFASS to refer 
to both oFASS- 5 and oFASS- 3. In oFASS- 5, grade 1 includes reac-
tions restricted to the oral cavity. Grades 2 to 5 may include oral 
symptoms, but other target organs are affected. Grading is based 
on the organ/system involved regardless of the type or number of 
specific symptoms present of that organ/system. Grades 2 and 3 in-
clude skin, eye/nose, digestive, and/or uterine involvement, either 
1 or more than 1 of them, respectively. Lx and/or BR involvement 
(even isolated) classifies a reaction as Grade 4, and CV and/or NS in-
volvement (even isolated) as grade 5. In grades 4 and 5, other target 
organ/systems of lower grades may be affected. oFASS- 3 is a simpli-
fied version, where mild corresponds to grade 1, moderate to grades 
2 and 3, and severe to grades 4 and 5 of the oFASS- 5.
2.1.3  |  Numerical Food Allergy Severity Score 
(nFASS)
The nFASS model was constructed from scratch and had to satisfy 
several conditions: (i) the nFASS must consistently map onto the 
oFASS (ie, higher oFASS implies higher nFASS, and a given nFASS 
value can only correspond to one level of oFASS); (ii) a higher num-
ber of symptoms within the same organ/system should increase the 
score.
The nFASS is computed in 3 steps as shown in the example of 
Table 2. Each organ/system has an assigned exponent, εo, (−1 for 











Mild Grade 1 Yes No No No
Moderate Grade 2 Yes/No 1 No No
Grade 3 Yes/No >1 No No
Severe Grade 4 Yes/No Yes/No 1 or both No
Grade 5 Yes/No Yes/No Yes/No 1 or both
Abbreviations: no, not involved; yes, involved; yes/no, it can be involved or not.
TA B L E  1  Ordinal Food Allergy Severity 
Score (oFASS) versions: oFASS- 3 and 
oFASS- 5
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symptom has an equivalence with the PRACTALL reference and an 
assigned weight, λs (Table S1). The small individual weights of the 
symptoms (λ < 0.1), combined with the organ/system exponents 
(from −1 to 4) that multiply the expression, guarantee correct map-
ping from the nFASS to the oFASS. Further details are in Appendix S2 
and Table S2.
2.2  |  Evaluation cohort
The evaluation was done in the EuroPrevall outpatient clinic data-
set that comprises 2112 patients and 8232 immediate food allergic 
reactions (characteristics in Tables S3 and S4, and the equivalence 
of symptoms with the PRACTALL reference in Table S5). Patients re-
porting reactions to foods were selected in 12 allergy clinics across 
Europe and evaluated following the same protocol previously de-
scribed.44 There was no exclusion based on age, type of food, or 
severity of reaction.
2.3  |  External validation cohorts
The external validation cohorts covered infants, children, and adults 
(n = 2930) selected across Europe, with immediate allergic reactions 
(n = 3622) to any type of food and of any severity (Table S3). These 
cohorts included patients from the EuroPrevall general population 
survey phase 3 (147 subjects, 635 food reactions),44,45 patients 
recruited in the iFAAM project (iFAAM cohort, 356 patients, 453 re-
actions)46,47; food- induced anaphylaxis from the Network for Online 
Registration of Anaphylaxis (NORA) (1959 subjects, 2020 anaphy-
laxis)4,7; infants and toddlers with egg and milk allergies recruited at 
Hospital Clinico San Carlos (Madrid, Spain) (HCSC cohort, 83 chil-
dren, 129 food reactions); and apple allergic patients recruited in the 
EU- funded SAFE project (385 subjects, 385 apple reactions).48 The 
equivalence of symptoms with the PRACTALL reference is presented 
in Table S5, and further information on the cohorts in Appendix S2.
2.4  |  Predictors and outcomes
The predictors are the 3 versions of FASS: oFASS- 3, oFASS- 5, and 
nFASS. In order to assess the ability of FASS (the acronym FASS com-
prises all three versions) to reflect reaction severity, we selected in 
the evaluation cohort outcomes (or severity indicators) that reflected 
management decisions taken by patients, carers and/or health profes-
sionals in the routine assistance of the 8232 food reactions included in 
the cohort. We assumed that a patient who requested emergency care 
assistance for a food reaction had a perception of higher severity than 
a patient who did not. Similarly, we assumed that a reaction that was 
treated with medication/s was considered more severe than a reaction 
not treated at all. We therefore selected from the information collected 
in the record forms of the validation cohort the following outcomes: 
request of emergency care, use of any medication, antihistamines, 
corticosteroids, and adrenaline. Any medication includes all the drugs 
TA B L E  2  Computing nFASS
Food reaction: boy 5 years, 15 min after eating peanut presents urticaria, red eyes, nausea, wheeze, and dizziness
Step 1 Step 2
Identify organ/system involved and the symptom PRACTALL equivalence to select the 
corresponding organ exponent and symptom weight
Compute one organ/system contribution 
(nFASSo)
Symptom in 
the reaction Organ System Exponent ε
Symptom equivalence 
PRACTALL Weight λ nFASSo = 2
0
(
1 + 1 +⋯ + n
)
Urticaria Skin O = 0 Generalized 
involvement (>10)





= 20 (1 + 0.08)= 1.08
Red eyes Eye 1 = 0 Intermittent rubbing 
of eyes





= 20 (1 + 0.05) = 1.05
Nausea GI 2 = 0 Complaints of nausea 
OR abdominal pain





= 20 (1 + 0.03) = 1.03
Wheeze Lower 
respiratory









= 22 (1 + 0.07)= 4.28




= 24 (1 + 0.05) = 16.8
Step 3







nFASS = log2(nFASSSkin + nFASSEye + nFASSGI + nFASSLoResp + nFASSNS) + 2 = log2(1.08 + 1.05 + 1.03 + 4.28 + 16.8) + 2 = 4.59 + 2 = 6.59
Abbreviations: GI, gastrointestinal; LoResp, lower respiratory; NS, nervous system.
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used to treat a reaction. An outcome named critical medical treatment 
(CMT) was built which included use of intravenous fluids (IVF), vaso-
pressors, oxygen, and/or mechanical ventilation. In the external valida-
tion cohorts, we used the outcomes for which FASS exhibited the best 
discrimination, classification, and calibration in the evaluation cohort. 
Outcomes different from the ones used in the evaluation phase could 
not be included in the external validation.42
2.5  |  Missing data
We excluded food reactions with missing information on the out-
comes in the evaluation and validation cohorts and no imputation 
was performed (ie, complete case analysis). Information on missing 
values is presented in Tables S6 and S7.
2.6  |  Survey of allergy healthcare professionals to 
appraise the performance of FASS
Separately, we undertook a global survey of allergy healthcare pro-
fessionals to rate the severity of different food- induced allergic re-
actions, using “Best- Worst Scaling” (BWS) which avoids user scale 
bias.49 In brief, an online “MaxDiff” survey was developed in which 
respondents were asked to rate the severity of different pairs of al-
lergic reaction scenarios and choose the pair that, in their opinion, 
reflected the maximum difference in severity. The pairs of allergic 
reaction scenarios were selected from a total of 32 vignettes pro-
viding a wide spectrum of reaction severity (Table S8). The survey 
was administered by an independent market Research company 
(ResearchNow, UK), with potential respondents contacted through 
the EAACI, Spanish Society of Allergy and Clinical Immunology 
(SEAIC), British Society for Allergy & Clinical Immunology (BSACI), 
and World Allergy Organization (WAO). Responses were volun-
tary, anonymous, and confidential (detailed information in Stafford 
et al50).
2.7  |  Statistical analysis
Descriptive statistics included frequency and percent for qualitative 
variables, and minimum, maximum, median, first, and third quartiles 
(Q1, Q3) for numerical variables. The Cochran- Armitage test for 
trend was used to analyze the frequency of outcomes across the 
oFASS levels.
In the evaluation of FASS, logistic regression models were gen-
erated for all outcomes. Models are presented with reference value, 
odds ratios (ORs) with their 95% confidence intervals (95% CI), and 
p- value for the Wald's test. FASS performance was assessed by ex-
amining discrimination, classification, and calibration. Discrimination 
was quantified by calculating the area under the curve (AUC) of 
the receiver operating characteristic (ROC) curve and its 95%CI. 
Classification measures included sensitivity (Se), specificity (Sp), 
positive and negative predictive values (PPV, NPV). For the calibra-
tion, predicted and observed (real) probabilities of the outcomes 
were calculated. The Hosmer- Lemeshow test for agreement was not 
applied because it is sensitive to grouping (thus, non- applicable to 
oFASS) and sample size (large N in evaluation cohort).42
Internal validation was performed by bootstrap with 100 rep-
licates applied over ROC- AUC. Bias and standard errors (SE) were 
estimated. External validation was done analyzing the predictive 
performance of FASS models in the external validation cohorts by 
logistic regression. ROC- AUC and 95%CI were calculated.
The responses to the MaxDiff survey were modeled and a 
“preference” score (representing severity) determined for each sce-
nario.50 These scores were compared to nFASS using Spearman's R 
correlation.
All statistical analyses were performed using R 4.0.3 and Python 
3.8.5. Significant level was set at p = .05.
2.8  |  Ethical considerations
The Institutional Review Board of HCSC (Madrid, Spain) confirmed 
that ethical approval was not required to the development and vali-
dation of FASS. The online survey of allergy healthcare professionals 
did not require ethical approval, but was approved by EAACI, SEAIC, 
BSACI, and WAO. ResearchNow follows the UK Market Research 
Society's Code of Conduct.
3  |  RESULTS
3.1  |  Evaluation of FASS
The FASS scores were implemented in the 8232 food reactions of 
the EuroPrevall outpatient clinic dataset (Tables S3 and S4). The 
frequency of the different symptoms is presented in Figure S1, and 
the severity distribution in Table 3. According to oFASS- 3, 35.8% of 
reactions were mild, 34.5% moderate, and 29.7% severe. The ma-
jority (78.8%) of moderate reactions were of Grade 2 (one organ/
system affected) accounting for 27.2% of total reactions. The most 
frequent severe reactions (81.1%) were of Grade 4 (Lx/BR) and 
represented 24.1% of total reactions. The nFASS values ranged 
from 1.07 to 7.75. All mild- grade 1 reactions had an nFASS value 
of 1.07 because they were all collected under one category (oro-
pharyngeal symptoms) in the EuroPrevall record forms. The nFASS 
values of moderate and severe reactions ranged from 2.01 to 3.98 
and from 4.07 to 7.75, respectively. The correct mapping of nFASS 
onto oFASS (Table 3) allows to understand the meaning of a given 
numerical score.
Logistic regression models were computed for oFASS- 3, oFASS- 5, 
and nFASS with any medication, adrenaline, corticosteroids, an-
tihistamine, CMT, and request of emergency care as outcomes. 
The frequency of the severity indicators increased progressively 
(Cochran- Armitage test for trend, p < .01) as the severity of reactions 
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increased with oFASS- 3 and oFASS- 5 (Table S9). A positive associa-
tion with all the severity indicators was found for the 3 versions of 
FASS, implying that a higher grade of oFASS- 3 and oFASS- 5, and an 
increment in the nFASS value (OR given per 1 point increment) was 
associated with higher probability of use of medications and request 
of emergency care to treat the reaction (Table 4). As presented in 
Table 4 and Figure 1A, all models had ROC- AUC>0.70 which is a 
requirement in model development.51 There is a trend for a progres-
sive increase of the ROC- AUC from oFASS- 3 to oFASS- 5 and nFASS. 
Furthermore, the ROC- AUC of the models with adrenaline (0.83– 
0.90), CMT (0.83– 0.91), and emergency care (0.78– 0.84) tended to 
be higher than those of either any medication (0.73– 0.76), cortico-
steroids (0.76– 0.80) or antihistamine (0.71– 0.73).
Classification measures of the models were calculated 
(Table S10). With the outcomes adrenaline and CMT, Se ranged from 
0.87 to 0.92 and Sp from 0.73 to 0.78. With emergency care, Se 
was around 0.70 and Sp 0.75. The PPVs ranged from 0.10 to 0.63 
depending on the prevalence of the severity indicators in the cohort 
(with higher outcome prevalence, higher PPV).
Predicted and observed (real) probabilities of the severity indi-
cators show that oFASS- 3, oFASS- 5, and nFASS are well calibrated 
(Table S11).
TA B L E  3  Severity of food reactions in the evaluation and external validation cohorts
Cohort
oFASS- 3 oFASS- 5 nFASS
Level N (%) Level N (%) Min Max Median (Q1, Q3)
Evaluation cohort
EuroPrevall Outpatient clinic cohort
N = 8232
Mild 2946 (35.8%) Grade 1 2946 (35.8%) 1.07 1.07 1.07 (1.07,1.07)
Moderate 2839 (34.5%) Grade 2 2236 (27.2%) 2.01 2.80 2.23 (2.11, 2.66)
Grade 3 603 (7.3%) 3.03 3.98 3.38 (3.12, 3.44)
Severe 2447 (29.7%) Grade 4 1984 (24.1%) 4.07 5.68 4.58 (4.39, 5.01)




Mild 0 Grade 1 0 – – – 
Moderate 210 (10.4%) Grade 2 68 (3.36%) 2.01 2.27 2.12 (2.09,2.2)
Grade 3 142 (7.02%) 3.04 3.74 3.12 (3.09,3.16)
Severe 1810 (89.6%) Grade 4 905 (44.8%) 4.08 5.68 4.69 (4.44,5.27)
Grade 5 905 (44.8%) 6.11 7.64 6.57 (6.47,7.15)
HCSC Infant Cohort
N = 129
Mild 15 (11.6%) Grade 1 15 (11.6%) 1.07 1.07 1.07 (1.07,1.07)
Moderate 101 (78.3%) Grade 2 66 (51.2%) 2.07 2.74 2.65 (2.11,2.68)
Grade 3 35 (27.1%) 3.07 3.44 3.12 (3.09,3.4)
Severe 13 (10.1%) Grade 4 10 (7.75%) 4.09 4.89 4.48 (4.42,4.64)




Mild 291 (45.8%) Grade 1 291 (45.8%) 1.07 1.07 1.07 (1.07,1.07)
Moderate 196 (30.9%) Grade 2 170 (26.8%) 2.01 2.74 2.65 (2.18, 2.67)
Grade 3 26 (4.1%) 3.03 3.43 3.37 (3.37,3.41)
Severe 148 (23.3%) Grade 4 138 (21.7%) 4.07 5.48 4.53 (4.24,5.17)
Grade 5 10 (1.57%) 6.11 6.8 6.75 (6.3,6.76)
SAFE
N = 385
Mild 230 (59.7%) Grade 1 230(59.7%) 1.07 1.07 1.07 (1.07,1.07)
Moderate 120 (31.2%) Grade 2 103 (26.8%) 2.07 2.68 2.65 (2.65,2.65)
Grade 3 17 (4.41%) 3.09 3.4 3.39 (3.39,3.39)
Severe 35 (9.09%) Grade 4 34 (8.83%) 4.26 4.79 4.54 (4.26,4.54)
Grade 5 1 (0.2%) 6.46 6.46 6.46 (6.46, 6.46)
iFAAM
N = 453
Mild 63 (13.9%) Grade 1 63 (13.9%) 1.07 1.07 1.07 (1.07,1.07)
Moderate 210 (46.4%) Grade 2 159 (35.1%) 2.01 2.75 2.13 (2.11,2.59)
Grade 3 51 (11.3%) 3.04 3.96 3.13 (3.09,3.38)
Severe 180 (39.7%) Grade 4 111 (24.5%) 4.07 5.63 4.52 (4.23, 4.69)
Grade 5 69 (15.2%) 6.07 7.55 6.56 (6.39,6.81)
Abbreviations: Max, maximum; Min, minimum; Q1, first quartile; Q3, third quartile.
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3.2  |  Internal validation
As a mechanism to account for overfitting of the FASS models, a 
bootstrap internal validation over the ROC- AUC was undertaken. 
The bias and SE results for all the outcomes (Table S12) show negli-
gible overestimation biases (1.0 × 10−6– 1.23 × 10−3).
3.3  |  External validation
The FASS scores were implemented in the food reactions of the 
external validation cohorts and the severity distributions are pre-
sented in Table 3. In the NORA cohort close to 90% were grade 4 
and 5 reactions in oFASS- 5, and 7.02% had systemic reactions with 
involvement of 2 or more organs (grade 3), which is consistent with 
the inclusion criteria in NORA.4,7 In contrast, in the SAFE cohort 
on apple allergic patients, close to 60% of patients had exclusively 
mild- grade 1 oropharyngeal symptoms, and severe reactions only 
appeared in 9% of subjects. It can be seen that nFASS mapped cor-
rectly onto oFASS for the 5 external validation cohorts.
In the external validation, we used the best 3 severity indica-
tors of the evaluation in terms of discrimination, classification, and 
calibration: adrenaline, CMT, and emergency care. The frequency of 
these outcomes increased significantly in all the cohorts as severity 
increased classified with oFASS (Table S13). The predictive perfor-
mance of FASS was evaluated using logistic regression. The ROC- 
AUC with their 95%CI are presented in Table 5 and those of nFASS in 
Figure 1B. Overall, there was a trend for lower ROC- AUC for oFASS- 3 
and higher for nFASS in all the cohorts. The ROC- AUC for the 3 FASS 
models were lower in NORA compared with the other cohorts.
3.4  |  Comparison of nFASS to the BWS ranking of 
allergy healthcare professionals
The responses of 334 allergy healthcare professionals were mod-
eled following BWS methodology, and a BWS score was assigned 
to each of the 32 food reaction scenarios. The reaction scenarios 
include information on the symptoms/signs and on the treatment 
given (or not), and the final outcome of the reaction. The severity 
of these reactions was also scored with FASS (Table S8). A strong 
correlation (Spearman R 0.89) was found between BWS and nFASS 
values (Figure S2), even if FASS severity scoring was derived solely 
on the basis of symptoms.
F I G U R E  1  A, Model evaluation: ROC curves for oFASS- 3, oFASS- 5, and nFASS in the EuroPrevall outpatient clinic cohort. B, External 
validation: ROC curves for the severity indicators with nFASS. TPR, true- positive rate; FPR, false- positive rate; ROC, receiver operating 
characteristic, CMT, critical medical treatment
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4  |  DISCUSSION
We have developed and validated a severity score of food allergic 
reactions with ordinal (oFASS- 3 and oFASS- 5) and numerical (nFASS) 
formats that map consistently. They have different granularity and 
are intended to be used by different stakeholders in different set-
tings. After a comprehensive validation following the TRIPOD 
statement42 (Table S14), FASS has proven to be a reliable and well 
calibrated method to describe severity of food allergic reactions. 
This was shown in the EuroPrevall outpatient clinic cohort used in 
the evaluation and was confirmed by bootstrap internal validation, 
and by external validation in 5 different cohorts that cover the whole 
spectrum of FA. Additionally, nFASS is strongly correlated to the 
classification of severity of food reaction scenarios done by expert 
allergy clinicians, further supporting the good performance of FASS.
For the validation, we selected as severity indicators (outcomes) 
the request of emergency care or the medications given to control 
the reactions, since they reflected management decisions taken 
by the patients themselves or by the clinicians providing medical 
care. The severity indicators were those collected in the forms of 
the evaluation cohort, with the CMT outcome built to identify the 
most severe ones. The variability in the management of allergic re-
actions and anaphylaxis and the underuse of adrenaline in relation 
to the recommendations9,52 might lead to a limitation of the selected 
outcomes. We have shown that the frequency of the outcomes 
significantly rose with increasing severity of reactions graded with 
oFASS in the evaluation cohort (Table S9). The discrimination, clas-
sification, and calibration of FASS were better for the outcomes of 
use of adrenaline, CMT and request of emergency care selected for 
the external validation (Figure 1A, Table 4, Tables S10 and S11), sug-
gesting that they are more appropriate severity indicators than use 
of any medication, antihistamine, and corticosteroids. Also in the 
external validation cohorts, the 3 selected outcomes significantly 
increased as severity increased by oFASS (Table S13). We thus be-
lieve our results support the adequacy of adrenaline, CMT and re-
quest of emergency care as severity indicators. Additionally, several 
studies52- 54 reporting that adrenaline administration by health pro-
fessionals increases with increasing severity of the allergic reactions 
support the selection of adrenaline as an outcome. This has been 
shown in the pre- hospital management of anaphylaxis by ambulance 
crew in Manchester, UK,53 in two pediatric emergency departments 
of Marseille, France,54 and in the management of severe allergic re-
actions done by health professionals of 10 European countries of the 
NORA network.52 With the external validation cohorts, we found an 
overall good predictive performance, especially of nFASS, with some 
limitations in the NORA cohort. Due to the fact that almost 90% of 
the reactions included in NORA were severe/grade 4– 5 (Table 3), 
the discrimination capacity of oFASS is limited (ROC- AUC<0.7) 
(Table 5). The best performance is found with nFASS for CMT (ROC- 




CMT ROC- AUC 
(95% CI)
Emergency care 
ROC- AUC (95% CI)
NORA cohort
N = 2020
N(%)# 400 (22.35%) 226 (12.6%) 1411 (69.88%)
oFASS- 3 0.53 (0.49, 0.58) 0.54 (0.48, 0.6) 0.53 (0.48, 0.57)
oFASS- 5 0.59 (0.55, 0.63) 0.65 (0.6, 0.69) 0.57 (0.54, 0.61)
nFASS 0.62 (0.59, 0.65) 0.7 (0.66, 0.73) 0.58 (0.56, 0.61)
HCSC Cohort
N = 129
N(%)# 4 (4.87%) 3 (2.3%) 37 (28.68%)
oFASS- 3 0.96 (0.91, 1.0) 0.96 (0.89, 1.0) 0.63 (0.46, 0.8)
oFASS- 5 0.98 (0.93, 1.0) 0.98 (0.94, 1.0) 0.65 (0.52, 0.79)




N(%)# 1 (0.15%) 0 15 (2.37%)
oFASS- 3 0.89 (0.66, 1.0) Not estimable 0.74 (0.61, 0.87)
oFASS- 5 0.89 (0.68, 1.0) 0.79 (0.65, 0.93)
nFASS 0.94 (0.91, 0.96) 0.77 (0.64, 0.89)
SAFE cohort
N = 385
N(%)# Information not collected 19 (5.02%)
oFASS- 3 0.81 (0.69,0.92)




N(%)# 52 (11.76%) 49 (11.08%) 35 (7.91%)
oFASS- 3 0.66 (0.60, 0.72) 0.75 (0.69, 0.80) 0.67 (0.60, 0.74)
oFASS- 5 0.70 (0.64, 0.77) 0.76 (0.70, 0.82) 0.72 (0.64, 0.80)
nFASS 0.72 (0.65, 0.78) 0.78 (0.72, 0.84) 0.74 (0.66, 0.82)
Note: #, percent of food reactions excluding those in which the severity indicator is missing (missing 
values shown in Table S7).
ROC- AUC, receiver operating characteristic area under the curve; 95% CI, 95% confidence interval.
TA B L E  5  External validation: logistic 
regression models with oFASS- 3, 
oFASS- 5, and nFASS
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more adequate outcome than adrenaline or request of emergency 
care for these anaphylaxis patients. Further work is needed to assess 
the performance of FASS with other outcomes for anaphylaxis (ie, 
number of adrenaline doses, intravenous adrenaline, intensive care 
admission), but since this information was not collected in the eval-
uation cohort, we could not analyze them in the external validation.
Like other scoring systems of allergic reactions, FASS has an an-
atomical basis,17- 29,31- 37 but includes some novel approaches in scor-
ing severity, present already in the (more conventional) oFASS.
Isolated oral symptoms (OAS) are included separately in oFASS- 3 
(mild) and oFASS- 5 (grade 1), because they are a local reaction, and 
frequently the only clinical manifestation of FA as can be seen in 
Tables 2 and 4. Actually, 30% of all the food reactions (3545 out 
of 11854) of the evaluation and validation cohorts would not have 
been properly classified without including such category. In the 
currently available grading systems applied in FA, OAS is either ab-
sent25,26,29,32 or included with symptoms of other organs under the 
same grade.27,28,31,33
In oFASS when the number of organ/systems involved increase, 
the severity increases, but reactions will only be considered severe 
(Table 1) if Lx, BR, CV, and/or NS are involved, even if isolated. When 
reactions involve the eye/nose, skin, GI tract, uterus, they are con-
sidered moderate in oFASS- 3. The oFASS- 5 provides more detail by 
dividing moderate reactions into grades 2 (1 target organ) and 3 (>1 
organ), and severe reactions into grades 4 (Lx/BR) and 5 (CV, NS). So 
with oFASS- 5, it can be seen in the evaluation and validation cohorts 
(Table 3) that the most frequent reactions among the moderate ones 
are those with only one organ/system affected (grade 2), and among 
the severe ones those with respiratory involvement (grade 4). The 
severe grade in oFASS- 3 and grades 4 and 5 in oFASS- 5 capture all 
the potentially life- threatening anaphylaxis.55,56
The anatomical approach to classify severity of oFASS- 3 is a 
simple, easy- to- remember system to identify the potentially life- 
threatening anaphylaxis and prompt the early use of adrenaline. It 
can thus be used to educate patients and their careers, healthcare 
professionals, and even non- healthcare professionals who may face 
food allergic reactions at work (eg, restaurants, schools). At a popu-
lation level, it may be useful for education and raising awareness of 
food anaphylaxis, and thus of interest for public health authorities. 
oFASS- 5 may be more informative for allergy healthcare profession-
als who need to document reactions with more detail, but even so, 
it is still a simple system easy- to- remember and use. In summary, 
oFASS- 3 may be of highest value for patients and non- healthcare 
professionals, and both oFASS- 3 and oFASS- 5 for all healthcare 
professionals in their clinical practice. Furthermore, oFASS- 3 and 
oFASS- 5 have shown to be reliable in measuring severity, with a 
trend for a better performance of oFASS- 5 (Tables 4 and 5) related 
to its higher level of detail.
In contrast to other ordinal systems, we have not considered in 
oFASS the intensity of the symptoms/signs of the organ/system af-
fected, or whether they are subjective or objective. This was done 
for the sake of simplicity and the intended use aforementioned. 
When more detail is required nFASS can be applied. As an example, 
a reaction with “skin involvement” will be classified as moderate with 
oFASS- 3 and grade 2 with oFASS- 5, regardless of whether the skin 
involvement is “mild pruritus” or “intense pruritus with generalized 
erythema, urticaria and angioedema.” However, the nFASS will score 
2.36 for the later and 2.01 for mild pruritus, and it is thus able to 
differentiate between these two reactions.
nFASS seems suitable for scoring reaction severity in clinical 
research settings and could help in the risk management of FA by 
including beside reference doses the severity parameter. We are 
currently exploring its usefulness in observational and intervention 
studies, analyzing the effect of cofactors and food allergen immuno-
therapy on the severity of food allergic reactions.
Further validation of FASS in other retrospective and, more im-
portantly, prospective cohorts in both clinical and research settings, 
is needed to refine this tool and confirm its reliability. FASS is based 
on the symptoms and organs affected which are not specific of food 
allergic reactions. Similar symptomatology and organ involvement 
can be observed in allergic reactions elicited by insect stings and 
drugs, and we are currently working in the adaptation and validation 
of FASS to allergy triggers other than foods.
In order to facilitate the use of FASS, we have developed a soft-
ware tool written in R language that allows to implement oFASS- 3, 
oFASS- 5, and nFASS in any dataset of food allergic reactions. The 
FASS tool is able to read any file in table format from Excel, SPSS, 
and STATA. The software tool, a tutorial and an example are avail-
able at Zenodo http://doi.org/10.5281/zenodo.4836276.
Through the FASS dissemination, widespread use, and further 
refinement, we can achieve the goal of improving education and im-
mediate care decisions of patients and clinicians, help advance re-
search, and guide the food industry and the health authorities.
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